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Platelets are anucleated blood cells that participate in a wide range of physiological and pathological functions. Their major role is
mediating haemostasis and thrombosis. In addition to these classic functions, platelets have emerged as important players in the
innate immune system. In particular, they interact with leukocytes, secrete pro- and anti-inﬂammatory factors, and express a
wide range of inﬂammatory receptors including Toll-like receptors (TLRs), for example, Toll-like receptor 4 (TLR4). TLR4,
which is the most extensively studied TLR in nucleated cells, recognises lipopolysaccharides (LPS) that are compounds of the
outer surface of Gram-negative bacteria. Unlike other TLRs, TLR4 is able to signal through both the MyD88-dependent and
MyD88-independent signalling pathways. Notably, despite both pathways culminating in the activation of transcription factors,
TLR4 has a prominent functional impact on platelet activity, haemostasis, and thrombosis. In this review, we summarise the
current knowledge on TLR4 signalling in platelets, critically discuss its impact on platelet function, and highlight the open
questions in this area.
1. Introduction
Platelets are small, anucleated, and short-lived blood cells
with a range of important functions beyond their classical
roles in haemostasis [1–3]. The function of platelets in
haemostasis has been well documented and is linked to their
capacity to respond to the damaged endothelium [4–6]. Fol-
lowing vessel damage and initial activation, platelets secrete a
wide variety of small molecules and proteins from intracellu-
lar granules in order to activate and recruit more circulating
platelets and immune cells, such as leukocytes [4]. In addi-
tion to these secretion events, platelets undergo dramatic
shape changes that enable them to cover the site of injury
and prevent bleeding [4]. Thrombosis (blood clot formation)
mediated by platelets occurs in the arteries under pathologi-
cal conditions and signiﬁcantly obstructs the blood ﬂow to
major organs such as the heart and brain resulting in heart
attacks and strokes, respectively [7]. In addition to their
physiological functions, platelets can be involved in diﬀerent
pathological conditions, for example, in atherosclerosis [8, 9].
If the atherosclerotic plaque ruptures, the exposure of the
subendothelial matrix and release of procoagulatory matrix
proteins, such as collagen, are suﬃcient to initiate the forma-
tion of a thrombus (blood clot) at this site [4, 10]. Thrombus
poses a signiﬁcant systemic risk because it is formed in a
narrowed blood vessel and so has the potential to completely
occlude the vessel and trigger a myocardial infarction or
ischaemic stroke [10].
Platelets also have pivotal roles in the innate immune
system, which includes cells that combat general infections
(e.g., neutrophils), and is responsible for the eradication of
pathogens to protect the body from infection [11, 12]. During
the immune response, platelets have been shown to interact
with and respond to many species of Gram-positive and
Gram-negative bacteria through diﬀerent receptors [13, 14].
Moreover, platelets are capable of internalising speciﬁc types
of bacteria and viruses although the function of this phenom-
enon is poorly understood [15, 16]. The ability of platelets to
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participate in such a wide range of functions and their ability
to synthesise certain new proteins despite lacking a nucleus
have generated signiﬁcant scientiﬁc interest [2, 3, 17].
In addition, platelets play a role in the development of
disseminated intravascular coagulation (DIC), a common
complication observed in patients with sepsis [18–20]. Dur-
ing DIC, platelets are activated and form smaller thrombi
in the microvasculature or aggregates that are sequestered
in organs such as the lungs. Together, this leads to thrombo-
cytopenia, a reduction in the number of circulating platelets.
Mild thrombocytopenia is deﬁned as less than 1.5× 1011
platelets per litre of blood compared to between 1.5 and
4.0× 1011 in healthy individuals, but more severe thrombocy-
topenia is deﬁned as less than 0.5× 1011 platelets per litre [6,
20, 21]. Furthermore, it has been discovered that platelets can
promote the formation of neutrophil extracellular traps
(NETs) which have cytotoxic actions on host cells beyond
their beneﬁcial antibacterial eﬀects [22].
Notably, conditions such as sepsis and DIC have been
suggested to be linked to several platelet receptors, especially
Toll-like receptor (TLR) 4 [8, 18, 22, 23]. In human nucleated
cells, especially in professional antigen-presenting cells, the
binding of a ligand to TLR1, 2, 4, 5, 6, 7, 8, 9, and 10 results
in the activation of the so called myeloid diﬀerentiation
factor-88- (MyD88-) dependent pathway, whereas TLR3
activates the MyD88-independent pathway [12, 23, 24].
In contrast to most TLRs which signal exclusively through
one of the two pathways, TLR4 is able to activate both
MyD88-dependent and MyD88-independent signalling
[12, 24].
Platelets contain all of the proteins (e.g., MyD88 and
interferon regulatory factor 3 (IRF3)) that are required for
signal transduction through TLR4 and so at ﬁrst glance it
would appear that platelets utilise the same mechanisms as
in nucleated cells [2, 25]. However, as we will explain in more
detail in the subsequent sections, this cannot be the case as
both the MyD88-dependent and the MyD88-independent
pathways culminate in the activation and nuclear transloca-
tion of transcription factors, and this step would not be appli-
cable in anucleated cells like platelets [2, 12, 26]. Before
examining the evidence for the TLR4 signalling pathways in
platelets, it is worth reviewing the pathways in nucleated cells
for use as a benchmark.
2. TLR4 Signalling in Nucleated Cells
2.1. TLR4 Ligands. Lipopolysaccharide (LPS) is a component
of Gram-negative bacterial cell membranes and a powerful
ligand for TLR4 [27, 28]. LPS is composed of a lipid Amoiety
(responsible for the molecule’s interactions with TLR4),
the core oligosaccharide, and the O-antigen polysaccharide
[27, 29, 30]. The lipid A moiety is localised in the outer
cell membrane and is formed from a 1,4-bis-phosphorylated
diglucosamine molecule linked to variable acyl chains (e.g.,
six chains in Escherichia coli LPS) [27, 29]. The phosphate
groups and acyl chains of LPS are important for interactions
with TLR4, and alterations in these can shift the molecule
from being an agonist to an antagonist [27, 31]. LPS may
not be the only ligand for TLR4 as damage-associated
molecular patterns (DAMPs), such as high-mobility group
box 1 (HMGB1) and heat shock proteins (HSPs), have also
been suggested to be capable of inducing activation through
this receptor [12, 32].
Although the immunogenic region of LPS is inside the
bacterial cell membrane, it is capable of eliciting an immune
response due to the presence of lipopolysaccharide-binding
protein (LBP) [27, 29, 33]. LBP is a soluble protein that is
synthesised by hepatocytes and found in the blood [28, 33].
It is capable of binding to areas rich in LPS (e.g., LPS
aggregates and Gram-negative bacterial membranes) and
promotes the exposure of the molecule’s hydrophobic
regions [34]. Subsequent to this, LPS monomers, via a pro-
cess facilitated by albumin, can associate with CD14 (cluster
of diﬀerentiation 14), a high aﬃnity, horse shoe-shaped,
glycosylphosphatidylinositol- (GPI-) anchored membrane
protein [28, 31, 33–35]. CD14 forms a dimer with the
dimerisation interface at the C-terminal end and LPS-
binding pockets at the N-terminal end [33]. The transfer
of LPS to TLR4 and the breakdown of LPS aggregates
(micelles) into monomers are mediated by CD14 [28, 31,
33, 36]. Albumin can bind LPS, and other hydrophobic
molecules, via hydrophobic interactions between domain
III (on albumin) and the fatty acid chains of LPS [34].
Furthermore, albumin is capable of transferring LPS to
TLR4 on its own although this requires approximately 10-
fold higher concentrations of LPS compared to CD14 [34].
2.2. TLR4 Receptor. Similarly to CD14 (the molecule respon-
sible for transferring LPS to TLR4), the ectodomains of TLR4
are horse shoe-shaped due to the presence of several leucine-
rich repeats (LRRs) [33, 37]. Like other type I membrane-
spanning proteins, the membrane-spanning domain of
TLR4 is comprised of a single helix that serves to link the
intracellular and extracellular domains [31]. The intracellular
domain of TLRs contains a Toll/IL-1 receptor (TIR) domain
common to all of the adaptor protein molecules involved at
this stage of signalling [1, 31].
For signalling via TLR4 to occur, TLR4 requires hetero-
meric association with myeloid diﬀerentiation factor 2
(MD-2) [38, 39] (Figure 1). MD-2 is required because TLR4
does not bind LPS directly [27]. This is exempliﬁed by
the ability of human MD-2 to bind LPS in the absence of
TLR4 [31]. MD-2 is constitutively associated with TLR4
through an interaction in the central region of TLR4 and
may be responsible for the recognition of diﬀerent LPS
chemotypes [33, 39].
TLR4 has been detected on the plasma membrane and in
intracellular compartments (such as the early endosome) of
both nucleated cells and platelets [24, 40, 41]. In addition,
TLR4 is capable of internalisation, as has been shown follow-
ing prolonged exposure to LPS [24, 40–42]. The mechanisms
behind the internalisation of TLR4 diﬀer between cell types
and may be required for MyD88-independent signalling
[40, 43]. The intracellular forms of TLRs are not inactive as
may be expected for an internalised extracellular receptor
but are capable of recognising ligands (such as LPS) in endo-
somes, lysosomes, and endolysosomes [12, 43, 44]. Notably,
plasma membrane localisation of TLR4 requires HSP
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90 kDa βmember 1 (gp96) and protein associated with TLR4
(PRAT4A) acting as chaperones [44, 45]. Moreover, MD-2
has been reported to play a role in TLR4 localisation at the
plasma membrane as its absence traps TLR4 in the Golgi
apparatus [38].
2.3. TLR4 Activation. In order to activate the TLR4 signalling
pathway, two receptor complexes need to dimerise to bring
together the intracellular TIR domains (Figure 1) [31]. LPS
and MD-2 (constitutively bound) binding to TLR4 is
required for the TLR4 complex dimerisation to take place
[27]. This dimerisation occurs due to the formation of a
dimerisation domain that incorporates a hydrophobic patch
on TLR4 and one of the acyl chains of LPS [33]. The remain-
ing acyl chains are hidden in the hydrophobic cavity of MD-2
[27]. Ectodomain dimerisation leads to an interaction
between the two intracellular domains of the TLR4 mono-
mers [31]. This builds a platform onto which the intracellular
signalling complexes can be formed [33]. At this stage, the
two pathways diverge but there is still disagreement about
what happens during this step [31].
2.4. The MyD88-Dependent Pathway. For the MyD88-
dependent pathway, the TIR domain-containing adaptor
protein (TIRAP), also known as MyD88 adaptor-like (Mal)
protein, interacts with the TIR domain of the receptor
enabling it to recruit MyD88 to the plasma membrane [31].
TIRAP presence at the plasma membrane is mediated by its
phosphatidylinositol-4,5-bisphosphate- (PI(4,5)P2-) binding
domain [43, 46]. It has been suggested that TIRAP may bind
to TLR4’s TIR domain using complementary charge distribu-
tions because of the observation that charges diﬀer between
TLR3 (cannot bind TIRAP) and TLR4 and TLR2 (can or only
bind TIRAP, resp.). However, the exact details and structures
involved during this binding have not been determined, par-
tially due to the lack of a crystal structure for the TIR domain
of TLR4 [31]. Once TIRAP has bound to the receptor, it
recruits MyD88 via an interaction between their respective
TIR domains [43, 46, 47].
MyD88 contains a death domain (DD) at its N-terminal
end, which is crucial for the subsequent signalling cascade
as it enables the construction of a large multimeric complex
called the Myddosome (Figure 2) [47]. The Myddosome is
formed of six MyD88, four interleukin- (IL-) 1 receptor-
associated kinase 4 (IRAK4), and four IRAK1/2 molecules,
all of which contain DDs, arranged in a single-stranded
left-handed helix [24, 47]. As shown in Figure 2, this helix
has multiple levels with the ﬁrst two levels comprised solely
of MyD88, IRAK4 is found in the third level, and IRAK1/2
is found in the fourth level [47]. Following assembly, IRAK4
undergoes an activating autophosphorylation process
thereby enabling it to phosphorylate, and activate, IRAK1/2
[47]. Phosphorylation of IRAK1/2 stimulates disassociation
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Figure 1: Structure of TLR4/MD-2 ectodomains, in a
heterotetrameric form, as seen from (a) or (b). The TLR4
molecule (green) is constitutively bound to MD-2 (magenta), and
the TLR4∗ (cyan) molecule is constitutively bound to MD-2∗
(yellow). Dimerisation interfaces form between TLR4 and MD-2∗
and vice versa. Images were created by adapting the structure of
TLR4 (PDB code: 3FXI) using PyMOL [37].
MyD88
IRAK4
IRAK1/2
Downstream
signalling
To TLR4
Figure 2: Structure of the Myddosome showing the protein death
domains (DD). The Myddosome is formed of six MyD88
molecules, four IRAK4 molecules, and four IRAK1/2 molecules
arranged in a single-stranded helix. MyD88 occupies the two
layers closest to the plasma membrane whereas IRAK4 and
IRAK1/2 form the two subsequent layers. The image was created
by adapting the structure of the Myddosome (PDB code: 3MOP)
using PyMOL [47].
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from the Myddosome and triggers polyubiquitination of
tumour necrosis factor (TNF) receptor-associated factor
(TRAF) 6 [47, 48]. TRAF6 interacts with TRAF-activated
kinase 1 (TAK) and IRAK1/2, and this complex in turn inter-
acts with NF-κB essential modulator (NEMO) to stimulate
the activating phosphorylation of IκB kinase- (IKK-) β and
the degradation of IκB [24, 49–51]. Degradation of IκB and
the release of inhibition on NF-κB permit it to translocate
into the nucleus and enhance expression of proinﬂamma-
tory cytokines including TNFα and IL-1β [44, 50, 51]. The
MyD88-dependent signalling downstream of LPS stimula-
tion is dependent on TLR4 remaining at the plasma mem-
brane as inhibition of internalisation increases NF-κB
activity [52].
Activation of mitogen-activated protein kinases
(MAPKs) downstream of MyD88 and TAK1 is also involved
in TLR4-mediated responses in nucleated cells [44, 48].
MAPKs include a range of proteins including extracellular
signal-regulated kinase (ERK) 1 and 2, c-Jun N-terminal
kinase (JNK) 1 and 2, and p38 [48]. These kinases are capable
of activating the transcription factor, activator protein 1
(AP-1) [48]. This part of the MyD88-dependent pathway
is dependent on the downregulation of TRAF3, via ubiqui-
tination by cellular inhibitor of apoptosis (cIAP), near the
plasma membrane where it has a negative regulatory role
[48]. A summary of all the signalling pathways in nucleated
cells is shown in Figure 3.
2.5. The MyD88-Independent Pathway. TRIF-related adaptor
molecule (TRAM) is responsible for recruiting TIR domain-
containing adaptor-inducing interferon-β (TRIF) in the
MyD88-independent pathway [31]. Signalling through this
pathway occurs following speciﬁc internalisation of the
TLR4-MD-2 heterotetramer, its bound ligand, and CD14
[53–55]. The protein responsible for the internalisation
(clathrin or caveolin) of TLR4 varies between cell types
and with time although dynamin and CD14 are always
necessary [40, 43, 52, 55]. Whereas CD14 is only required
at low concentrations of LPS for MyD88-dependent path-
way signalling (with other proteins such as albumin capa-
ble of transferring LPS to MD-2), CD14 is always
necessary for MyD88-independent signalling [34, 55, 56].
As internalisation of TLR4 occurs, the decrease in PI(4,5)P2
in the local area leads to a weakening of the interaction
between TLR4 and TIRAP and thus propagates the break-
down of the Myddosome [24, 43]. Interestingly, endocytosis
of TLR4 does not appear to be dependent on TLR4-
mediated signalling, with cells lacking TIRAP, MyD88,
TRAM, or TRIF retaining the capacity to internalise the
receptor [55]. This has been suggested to be a result of phos-
pholipase Cγ2 (PLCγ2) and spleen-associated tyrosine
kinase (Syk) activation in a CD14-dependent and TLR4-
independent manner [55].
Upon internalisation, TLR4 enters the endosome, a
region of the cell where TRAM and TRAF3 are present and
from where MyD88-independent signalling can begin [24,
43, 48, 55]. When recruited to the TLR4-TRAM-TRIF com-
plex by TRIF, TRAF3 is polyubiquitinated thus stimulating
the activation of TRAF family member-associated NF-κB
activator- (TANK-) binding kinase- (TBK-) 1 and IKKε
[48]. TBK1 and IKKε are then free to phosphorylate IRF3,
which is activated upon phosphorylation and dimerisation
and stimulates the production of type I interferons [48, 56].
3. TLR4 Signalling in Platelets
3.1. Platelet Activation upon Vascular Damage. The response
of platelets to “classical” agonists and the subsequent activa-
tion in haemostasis have been well deﬁned [4–6]. During vas-
cular injury, there is exposure of the subendothelial matrix
and proaggregatory proteins, such as von Willebrand factor
(vWF) and collagen, to the ﬂow of blood. vWF is immobi-
lised on collagen, and its association with GPIb-V-IX, a large
glycoprotein (GP) complex, represents the initial interaction
between platelets and the damaged vessel. This interaction
slows down the platelets enabling them to interact with the
exposed collagen via GPVI and platelet activation to ensue
[57–59]. Binding of collagen to GPVI promotes an intracellu-
lar signalling cascade involving tyrosine kinase-mediated
(e.g., Syk) activation of PLCγ2. The degradation of
PI(4,5)P2 by PLCγ2 into diacylglycerol (DAG) and inositol
1,4,5-trisphosphate (Ins(1,4,5)P3, also known as IP3) induces
indirect activation of protein kinase C (PKC) [59].
Platelet activation induces shape change and modulation
of integrin αIIbβ3 aﬃnity to allow the formation of a platelet
plug with ﬁbrinogen used as a bridging molecule to sur-
rounding platelets [5, 6]. Integrin activation is critical for a
successful aggregation response. In resting platelets, integrin
αIIbβ3 is in a low aﬃnity state but a conformational change
during platelet activation enables high-aﬃnity binding of
ligands. PKC activation has a key role in modulating integrin
αIIbβ3 aﬃnity [59, 60].
Furthermore, activation of platelets leads to degranula-
tion and the secretion of adenosine diphosphate (ADP)
and the synthesis and release of thromboxane A2 (TxA2),
resulting in the activation of more platelets and recruit-
ment of them to the thrombus [57–59]. Moreover, pro-
thrombin is cleaved into thrombin following interactions
involving tissue factor, factor VIIa, and factor Xa on the
activated platelet surface. Thrombin is able to activate
platelets through a cleavage of a region in the extracellular
domains of protease-activated receptors (PARs) 1 and 4.
Together, these agonists activate more circulating platelets
and thus stimulate the formation of a platelet plug to seal
the damaged region [5–7].
3.2. TLR4 Expression in Platelets. The presence of TLR4 on
platelets is not disputed, and it was ﬁrst identiﬁed on mouse
and human platelets using ﬂow cytometry by Andonegui
et al. [36]. In addition, the same research group demon-
strated that TLR4 displays functional eﬀects in platelets.
Furthermore, the discovery was backed up independently
by Cognasse et al. in the same year, also through ﬂow
cytometry-based experiments [41]. Other research groups
have also conﬁrmed the presence of TLR4 on platelets
through immunoblot analysis [42, 61, 62]. The amount of
TLR4 expressed on the surface of platelets is variable, and
an intracellular pool has also been identiﬁed [30, 41, 42].
4 Mediators of Inﬂammation
A big diﬀerence in TLR4 signalling between platelets and
nucleated cells is that although platelets contain the intra-
cellular signalling proteins required for TLR signalling
(Figure 4), they do not have all of the necessary extracellular
components (e.g., CD14) [2, 63, 64]. Membrane-bound
CD14 is absent in platelets; however, this problem is
overcome by high levels of soluble CD14 in the plasma
[14, 30, 63, 65]. This may prevent “priming” of platelets
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Figure 3: Summary of intracellular TLR4 signalling pathways in nucleated cells. LPS is transferred to CD14 (or albumin), via a process
involving LBP and albumin, which transfers LPS to TLR4:MD-2 to complete the heterotetramerisation. There are two major signalling
pathways, namely, the MyD88-dependent and -independent pathways, for TLR4 signalling. In the MyD88-dependent pathway, TIRAP (or
Mal) enables MyD88 binding to TLR4 and formation of the Myddosome, which contains MyD88, IRAK4, and IRAK1/2. The kinases
found at the base of the Myddosome activate TRAF6 and TAK1 followed by the activation of NEMO and its associated kinases. IKKβ
stimulates the degradation of inhibitory IκB, which leads to nuclear translocation of NF-κB and transcription of proinﬂammatory genes.
In addition, TAK1 activates JNK1/2, ERK1/2, and p38, which can then stimulate the transcription factor AP-1. In the MyD88-
independent pathway, following CD14-dependent internalisation into the endosomes, TRAM and TRIF are recruited to TLR4 before
activating TRAF3. Activation of TRAF3 activates TBK1 and IKKε, which phosphorylate and activate the transcription factor IRF3 that
stimulates the transcription of anti-inﬂammatory cytokines.
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at low concentrations of LPS whilst responses at higher
concentrations are not aﬀected. Moreover, the requirement
for higher concentrations of LPS could prevent NET forma-
tion in response to minor bacterial infections, thus protecting
against unwarranted endothelial damage [22]. Furthermore,
the absence of membrane-bound CD14 may also have an
impact on MyD88-independent signalling which requires
CD14 for the endocytosis of TLR4 and LPS [55]. The loss
of CD14 caused by “washing” platelets appears to reduce
the magnitude of the response to LPS although a response
is still present [63, 66, 67].
3.3. TLR4 Activity in Platelets. A strong piece of evidence for
TLR4 activity in platelets comes from experiments conducted
by Clark et al. They demonstrated that high concentrations of
LPS led to an interaction between platelets and neutrophils
that stimulated the formation of NETs [22]. The researchers
also linked this activity to sepsis, a disease that is commonly
associated with platelet TLR4 [19]. This was achieved by
determining the production of NETs in the blood samples
of sepsis patients [22]. It is unclear whether it was the LPS
in the blood or another substance that stimulated this
response as certain proteins that may stimulate platelets in
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Figure 4: Summary of intracellular TLR4 signalling in platelets. Although the individual steps of the MyD88-dependent pathway have been
observed, signalling in its entirety downstream of TLR4 has not been conﬁrmed. Similar to nucleated cells, the proteins required for signalling
through MyD88-dependent and -independent pathways are present in platelets but it is currently unclear how they mediate their eﬀects.
Signalling downstream of MyD88 can also be mediated by cGKI. The presences of TLR4, MyD88, IRAK1, TRAF6, TAK1, JNK, MAPK,
IκBα, NF-κB, TRIF, TRAF3, TBK1, IKKε, and IRF3 have all been conﬁrmed by immunoblot analysis [2, 25]. Question marks (?) denote
aspects of the pathway that have not been conﬁrmed.
6 Mediators of Inﬂammation
a TLR4-dependent manner are also released into the blood
during sepsis, for example, HMGB1 [22, 32]. Similarly, fur-
ther evidence for the role of platelet TLR4 is provided by the
observation that the levels of soluble cluster of diﬀerentiation
40 ligand (sCD40L) are raised following treatment of platelets
with LPS [63, 66–69]. This is important because platelet
α-granules are the largest source of sCD40L, and CD40L is
involved in inﬂammatory responses elucidated by the endo-
thelium and immune cells [1, 68–70]. Increases in sCD40L
levels have been suggested to directly involve TLR4 [69].
Many attempts have been made to characterise the
responses of platelets to LPS and other TLR4 agonists
although there have been conﬂicting results. Evidence from
diﬀerent studies agree that exposure of platelets to LPS stim-
ulates the release of tumour necrosis factor- (TNF-) α, a mol-
ecule that is produced downstream of the MyD88-dependent
pathway in nucleated cells [42, 50, 71]. Although platelets
lack genomic DNA, they still contain mRNA transcripts
that can be processed and spliced following stimulation
of platelets by LPS or thrombin [63, 72]. Transcripts that
are aﬀected include IL-1β (a proinﬂammatory cytokine)
and cyclooxygenase-2 (produces a platelet agonist, TxA2)
[63]. In addition, IL-1β mRNA has been shown to be
spliced in platelets in a TLR4-dependent manner with JNK
and protein kinase B (PKB) (found downstream of the
MyD88-dependent pathway) activity increasing during splic-
ing [65]. Furthermore, splicing of IL-1β was diminished in
the presence of JNK or PKB inhibitors. However, the mech-
anism of action has not yet been elucidated [65]. Platelet
shape change as a result of actin ﬁlament formation has also
been suggested [63]. A comprehensive examination of
cytokine release from platelets after treatment with LPS
was conducted by Cognasse et al. [30]. They demonstrated
that the expression of CD63 and release of sCD40L and
platelet-activating factor 4 (PAF4) were increased; release
of regulated upon activation, normally T-expressed, and
presumably secreted (RANTES), angiogenin and platelet-
derived growth factor- (PDGF-) AB were decreased (along
with TLR4 expression); meanwhile, there was no change
in the expression of soluble P-selectin, epidermal growth
factor (EGF), transforming growth factor β (TGFβ), or
IL-8 [30]. Upregulation of P-selectin following LPS expo-
sure is controversial with evidence both for [32, 61, 63]
and against [26, 30, 66].
3.4. The Role of MyD88 in Platelets. It is unclear whether the
traditional TLR4 pathways are responsible for all the eﬀects
mediated by TLR4 ligands on platelet function. MyD88−/−
mouse platelets have been used to demonstrate that this
protein is necessary for the eﬀects of LPS in enhancing
aggregation and granule secretion in platelets. Some eﬀects
downstream of MyD88 have also been shown to be mediated
by the cyclic guanosine monophosphate- (cGMP-) mediated
signalling pathway [61].
In contrast, one research study demonstrates that there
is virtually no role for MyD88 in modulating platelet func-
tion during Gram-negative (Klebsiella pneumoniae) bacte-
rial infection [71]. Diﬀerences in responses were observed
in systemic MyD88−/−mice compared to the controls;
however, these diﬀerences could not be recovered by
transfusing wild-type platelets into the MyD88−/− mice.
Furthermore, some changes in the secretion of TNFα
and monocyte chemoattractant protein-1 (MCP-1) were
observed that could be the result of deletion of platelet
MyD88, thus suggesting that signalling to NF-κB is still
intact and functioning [71].
The results of this study are somewhat limited for several
reasons. For example, the observed eﬀects were not shown to
be mediated by TLR4 as competitive antagonists, blocking
antibodies for TLR4, and platelets derived from TLR4-
deﬁcient mice were not used in their experimental settings.
Furthermore, this study did not use pure LPS (or other
potential TLR4 ligands), but rather whole Klebsiella pneumo-
niae bacteria, which means that other bacterial components
or exotoxins may have been able to inﬂuence cellular activi-
ties. More speciﬁcally, there was no investigation into the
success of the platelet transfusions as the recipient mice were
not depleted of their platelets and transfused platelets may
have been sequestered in organs such as the lungs and spleen.
The possibility of adaptive mechanisms in the MyD88-
deﬁcient mice was not investigated either; nor was an alterna-
tive signalling pathway suggested. Nevertheless, this study
highlights the necessity for further research in order to con-
ﬁrm the signiﬁcance of MyD88 in TLR4-mediated signalling
in platelets.
3.5. Priming Platelets. There is evidence suggesting that LPS
(and therefore TLR4-mediated signalling) has a “priming”
role in platelets. LPS on its own is unable to induce aggrega-
tion in washed platelets, but it can potentiate agonist-induced
aggregation responses. This was elucidated through the use
of classical agonists such as collagen and thrombin [14, 26,
61]. Despite washed platelets being used, sCD14 was still
detectable on platelets via ﬂow cytometry [61]. Similar
results have been obtained with platelet-rich plasma (PRP)
using agonists such as adenosine diphosphate (ADP) [63].
The response was mediated by TLR4 as demonstrated
through the use of TLR4−/− mouse platelets [61]. An intrigu-
ing observation from this was that the diﬀerent bacterial
strains of LPS tested had diﬀerent potencies [61]. This
has also been observed with the LPS from Rhodobacter
sphaeroides demonstrating its ability to act as a competi-
tive TLR4 antagonist [63]. This priming behaviour in
platelets is also supported by studies using NF-κB and
IKKβ inhibitors [26, 73, 74].
The identiﬁcation of TLR4:MyD88 coupling to the
cGMP-dependent pathway is important as this pathway
stimulates platelet aggregation from a subthreshold concen-
tration of an agonist (0.02U/mL of thrombin) [75]. Thus,
there is a precedent for TLR4 to have a priming role in plate-
let aggregation. The response to cGMP-analogues was
biphasic with an initial stimulatory response followed by an
inhibitory response [75]. An interesting point to consider is
that whilst cGMP-dependent kinase I (cGKI) inhibition
aﬀected aggregation and secretion to low agonist concentra-
tions (excluding ADP), there was no eﬀect on calcium
mobilisation [76] and TLR4 is also incapable of modulat-
ing calcium mobilisation [77]. cGKI has been proposed to
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be involved positively in the Gi-pathway, and so activation of
cGKI could help amplify platelet responses in a similar man-
ner to the P2Y12 receptor [76].
3.6. NF-κB in Platelets. Given that platelets lack a nucleus, it
may appear that the presence of a signal transduction path-
way that culminates in transcription factor activation would
have no role in platelet function. This initially prompted
some researchers to claim that TLR4 and its downstream
signalling proteins in platelets were relics left over from
their formation by megakaryocytes. Furthermore, certain
experiments concluded that there were no responses medi-
ated by TLR4 with speciﬁc bacterial species, lending support
to this argument [78]. Other concerns arose from diﬀerent
LPS chemotypes derived from diverse bacterial species hav-
ing diverse potencies when it comes to elucidating a response
[61, 63, 66, 79]. NF-κB, however, appears to have a role in
platelet function, suggesting a nongenomic role, especially
when the ability of NF-κB inhibitors to reduce the proaggre-
gatory eﬀects of TLR4 is considered [26, 80].
Notably, IKKβ is involved in the phosphorylation of sol-
uble N-ethylmaleimide-sensitive factor attachment protein
receptors (SNAREs), particularly synaptosomal-associated
protein 23 (SNAP23), and thus, IKKβ has an important role
in granular secretion [73]. Phosphorylation of SNAREs is
known to occur downstream of PKC when thrombin is used
as an agonist [73]. This is relevant because IKKβ is found
downstream of both this classical agonist pathway and the
MyD88-dependent pathway, suggesting a mechanism by
which TLR4 activation could lead to the secretion of granules
that has been shown in some studies [32, 51, 73]. Further
investigations have revealed that IKKβ activity occurs down-
stream of TAK1, found in the MyD88-dependent pathway
[25]. This evidence points towards the ability of the
MyD88-dependent pathway to promote SNARE complex
formation and may explain some of the “priming” activity
induced by TLR4 ligands. However, it is unclear whether
IKKβ directly phosphorylates SNAP23 or whether it occurs
due to the activation of NF-κB. It has been shown that NF-
κB activity is involved in modulating dense and α-granule
secretion upon activation with low agonist doses by using
inhibitors of IκBα phosphorylation and ubiquitination (to
indirectly inhibit NF-κB activity) [74, 80]. Moreover, NF-
κB inhibition decreases binding of platelets to ﬁbrinogen
[80]. This suggests that NF-κB is responsible for modulating
secretion in this case although one of the inhibitors used is
likely to directly inhibit IKKβ. Inhibition of aggregation has
also been seen to be mediated by NF-κB inhibitors down-
stream of TLR4, suggesting that TLR4 and NF-κB activity is
connected in platelets [26].
3.7. Other Ligands. Although LPS has been the predominant
ligand mentioned in this review, other ligands have also been
suggested to bind to TLR4; however, this area is highly con-
troversial [9, 67, 81, 82]. HMGB1 is one such possible ligand
and has been shown to have eﬀects in platelets in an auto-
crine and paracrine manner [32]. With a presence in the
plasma and on NETs, the DNA-binding protein released
from dead/dying cells or activated immune cells has
opportunities to interact with platelets in many conditions,
for example, sepsis [22, 32, 83, 84]. HMGB1 has been
reported to elicit similar responses in platelets compared to
LPS, including the priming eﬀects. These eﬀects were also
shown to involve TLR4, MyD88, and cGKI although there
is not yet clear evidence indicating exactly how these proteins
relate. ERK was another protein that had a change in its
activity as a result of treatment with HMGB1 dependent on
the presence of TLR4 [32]. HMGB1 has also been shown to
have a role in tumour metastasis in a mechanism involving
TLR4 [84]. Platelets are known to aid in cancer metastasis
by forming protective thrombi around metastasising cells
[85], and subsequent experiments by Yu et al. demonstrated
that deletion of TLR4 in mice led to fewer metastatic tumours
[84]. However, evidence from nucleated cells exists implying
that HMGB1 acts solely as a TLR ligand-binding protein
(e.g., LPS) and potentiates signalling through TLRs (alarmin
eﬀect) [86, 87]. Thus, the eﬀects observed in the studies might
be due to the binding of HMGB1-LPS colligation to TLR4
[87]. Moreover, recent studies have shown that, instead of
direct binding to TLR4, HMGB1 directly exerts eﬀects (such
as activation of NF-κB andMAPKs) on cells through binding
to the receptor for advanced glycosylation end-products
(RAGE) [88].
Another ligand that has been suggested to alter platelet
activity in a TLR4-dependent manner is cellular ﬁbronectin
[9]. It has been shown that cellular ﬁbronectin can modify
platelet activity in a similar manner to LPS by potentiating
aggregation induced by low doses of thrombin and increasing
phosphorylation of NF-κB and IKKα/β [9]. Furthermore, it
was shown that the presence of TLR4 in mouse platelets
signiﬁcantly increased thrombus growth when treated with
cellular ﬁbronectin [9]. These ﬁndings suggest a possible
eﬀect of cellular ﬁbronectin that may be mediated in a
TLR4-dependent manner.
Histones have also been proposed to be ligands for TLR4
and are found in the blood during sepsis following release
from neutrophils or necrotic cells [89–92]. They are impor-
tant for the organisation of DNA in nucleated cells and, like
HMGB1, appear in NETs [93]. Histones (especially H4) have
interactions in the blood, and they have been reported to
have a role in chemokine production in whole blood, platelet
aggregation, and also thrombocytopenia in mice [89, 93].
However, these studies concluded that it was monocytes,
and not platelets, that were responsible for the TLR4-
dependent production of cytokines (even though histone
H4 did associate with platelets) whereas the impact of
TLR4 on histone-induced aggregation and thrombocytope-
nia was not examined [89, 93]. In contrast, it has been shown
that histones can stimulate P-selectin exposure and thrombin
generation on platelets in a TLR2- and TLR4-dependent
manner [81].
Additionally, HSP60, a cell-stress marker, has been
proposed to trigger TLR4-mediated signalling in a vascular
smooth muscle cell line, with implications in atherosclerosis.
However, the eﬀects of this protein have not been tested on
platelets despite an increased expression of HSP60 on endo-
thelial cells in sheer stress environments [94, 95]. Serum
amyloid A (SAA) is a potential ligand for TLR4 that is
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released, primarily from the liver, during an inﬂammatory
response [96, 97]. Platelets have been shown to adhere to
SAA in an integrin αIIbβ3-dependent manner; however, it
has not been determined whether or not this integrin is solely
responsible for this behaviour as the research was conducted
before the discovery of TLR4 on platelets [97]. Further
research is required to determine whether these proposed
ligands are having an eﬀect due to direct binding to TLR4
or if it is the result of a more complex interaction, as has been
suggested for HMGB1 [87].
4. TLR4 Signalling in Platelets: What Is
Still to Discover?
Although many studies have linked TLR4 activity in platelets
to immune responses, there have not been many studies to
explore the signalling pathways downstream of TLR4 or
MyD88 [26, 32, 61]. This is of particular interest as this
receptor, with so many potential ligands and possible func-
tions, operates through a pathway that classically results in
gene transcription, but this end result is not achievable due
to the lack of a nucleus in platelets. Moreover, the presence
of all the signalling proteins in the pathways has been con-
ﬁrmed [2, 25] but whether the entirety of each pathway is
functional, in platelets, has not been elucidated. Currently,
individual steps of the MyD88-dependent pathway have
been seen but not tied together downstream of TLR4. The
MyD88-independent pathway in platelets also lacks consid-
erable amounts of detail, including study of its activity. Fur-
thermore, platelet TLR4 expression levels have been linked
to more severe disease states in inﬂammatory responses [8,
9, 81, 84, 98–101]. This obviously makes TLR4 an interesting
receptor to target for the prevention and/or treatment of
cardiovascular diseases. However, it is challenging due to
the important contribution of TLR4 to innate immunity.
Determination of the eﬀector proteins involved and their
responses may lead to the discovery of novel pathways
downstream of TLRs and present TLR4 as a novel therapeu-
tic target for the treatment of cardiovascular diseases and
other pathological settings such as inﬂammatory disease.
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